Virtual Library
Start Your Search
S. Mandrekar
Moderator of
-
+
MS 01 - Clinical Development of Novel Agents (ID 523)
- Event: WCLC 2017
- Type: Mini Symposium
- Track: Clinical Design, Statistics and Clinical Trials
- Presentations: 4
- Moderators:S. Mandrekar, M. Mori
- Coordinates: 10/16/2017, 11:00 - 12:30, Main Hall
-
+
MS 01.01 - Expansion Cohorts in Phase I Trials: Non Controlled Phase II or Translational Science? (ID 7640)
11:00 - 11:20 | Presenting Author(s): Benjamin Besse
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
MS 01.02 - Are We Categorizing Biomarkers Too Quickly? (ID 7641)
11:20 - 11:40 | Presenting Author(s): Jack Lee
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
MS 01.03 - Innovative Trial Designs: What is the Minimal Burden of Proof for Drug Approval? (ID 7642)
11:40 - 12:00 | Presenting Author(s): Giuseppe Giaccone
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
MS 01.04 - Is "Big Data" the Solution to the Complex Therapeutic Landscape? (ID 7643)
12:00 - 12:20 | Presenting Author(s): Yu Shyr
- Abstract
- Presentation
Abstract:
The Holy Grail of precision medicine is the comprehensive integration of patient genotypic with phenotypic data to develop personalized disease prevention and treatment strategies. Single cell sequencing, single cell mass cytometry (CyTOF), microbiome, and other types of high-throughput assays have exploded in popularity in recent years. The ability to generate big data brings us one step closer to the realization of precision medicine; nevertheless, across the life cycle of such data, from experimental design to data capture, management, analysis, and utilization, many challenges remain. In this session, I will discuss the artificial intelligence in cancer research, common statistical and bioinformatic mistakes for designing, analyzing, and interpreting the Omics based biomarker research. I will also discuss potential pathways for the seamless integration of cellular and molecular data with clinical, behavioral, and environmental parameters – a critical next step in advancing the goals of precision medicine.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
